viernes, 19 de diciembre de 2025

Are blood pressure disparities affecting mortality (Medscape AI) +... +++ ++ +++

Racial and other disparities in blood pressure (BP) control contribute substantially to differences in cardiovascular and all-cause mortality. https://www.medscape.com/ai-search?query=Are%20blood%20pressure%20disparities%20affecting%20mortality&ecd=mkm_ret_251219_mscpmrk_broad_disparity_etid7967633&uac=148436CN&impID=7967633 INEQUITIES IN CLINICAL OUTCOMES Hidden ECG Patterns Reveal Race & Wealth Links AI Model Can Distinguish Race From ECG Readings in People With Higher Socioeconomic Status Brian Owens https://www.medscape.com/viewarticle/ai-model-can-distinguish-race-ecg-readings-people-higher-2025a1000rvo?ecd=mkm_ret_251219_mscpmrk_broad_disparity_etid7967633&uac=148436CN&impID=7967633 October 16, 2025 Steeper Survival Odds in These Patients AML: Clinical Data Confirms Lower Survival in Black Patients Randy Dotinga https://www.medscape.com/viewarticle/aml-clinical-data-confirms-lower-survival-black-patients-2025a1000y86?ecd=mkm_ret_251219_mscpmrk_broad_disparity_etid7967633&uac=148436CN&impID=7967633 December 07, 2025 Unspoken Bias Changing How Patients Are Treated Weight Bias in the Hospital: Implicit Attitudes Shape Care Julie Peck https://www.medscape.com/viewarticle/weight-bias-hospital-implicit-attitudes-shape-care-2025a1000xmt?ecd=mkm_ret_251219_mscpmrk_broad_disparity_etid7967633&uac=148436CN&impID=7967633 December 02, 2025 TECH & ACCESS BIASES Are Subjective Scores Blocking Progress? Bias, Subjective Outcomes Slow AI Advances in Dermatology Marcia Frellick https://www.medscape.com/viewarticle/bias-subjective-outcomes-slow-ai-advances-dermatology-2025a1000w0y?ecd=mkm_ret_251219_mscpmrk_broad_disparity_etid7967633&uac=148436CN&impID=7967633 November 18, 2025 STI Testing Falls Short for Certain Communities Low Rates Seen With Packaged STI Testing, With Substantial Racial, Ethnic, Age, and Insurance Status Disparities Tara Haelle https://www.medscape.com/viewarticle/low-rates-seen-packaged-sti-testing-substantial-racial-2025a1000u49?ecd=mkm_ret_251219_mscpmrk_broad_disparity_etid7967633&uac=148436CN&impID=7967633 November 03, 2025 SOCIOECONOMIC DIVIDES New Self-Care Strategies Highlight Global Inequity Personalized Self-Management Empowers Patients With Chronic Respiratory Disease, but Global Inequities Persist Manuela Callari https://www.medscape.com/viewarticle/personalized-self-management-empowers-patients-chronic-2025a1000rxb?ecd=mkm_ret_251219_mscpmrk_broad_disparity_etid7967633&uac=148436CN&impID=7967633 October 16, 2025 New Med School Initiative Transforms Local Care Rx for the Neighborhood: Community Medicine Programs in Med School Lambeth Hochwald https://www.medscape.com/viewarticle/rx-neighborhood-community-medicine-programs-med-school-2025a1000so2?ecd=mkm_ret_251219_mscpmrk_broad_disparity_etid7967633&uac=148436CN&impID=7967633 October 22, 2025 Overlooked Signs Putting Patients at Risk Barriers to Timely Melanoma Diagnoses for Latino Patients: Study Points to Solutions Jennifer Lightowler, MMSc, PA-C https://www.medscape.com/viewarticle/barriers-timely-melanoma-diagnoses-latino-patients-study-2025a1000rc8?ecd=mkm_ret_251219_mscpmrk_broad_disparity_etid7967633&uac=148436CN&impID=7967633 October 10, 2025

Is Dark Skin the Blind Spot of Dermatology? ++++ +++ +++

TRENDING Is Dark Skin the Blind Spot of Dermatology? Is Dark Skin the Blind Spot of Dermatology? Carolin Hellerich https://www.medscape.com/viewarticle/dark-skin-blind-spot-dermatology-2025a1000y38?ecd=mkm_ret_251218_mscpmrk_derm_skin-disorders_etid7963642&uac=148436CN&impID=7963642 Medscape Europe December 05, 2025 Vitamin D: 4 Things You May Not Know Vitamin D: 4 Things You May Not Know David Warmflash, MD https://www.medscape.com/viewarticle/vitamin-d-4-things-you-may-not-know-2025a1000yhi?ecd=mkm_ret_251218_mscpmrk_derm_skin-disorders_etid7963642&uac=148436CN&impID=7963642 December 09, 2025 Inflammation Pursued as Target to Slow Skin Aging As a Key Driver, Inflammation Considered a Key Target for Anti-Skin-Aging Rxs Ted Bosworth https://www.medscape.com/viewarticle/key-driver-inflammation-considered-key-target-anti-skin-2025a1000z29?ecd=mkm_ret_251218_mscpmrk_derm_skin-disorders_etid7963642&uac=148436CN&impID=7963642 December 15, 2025 Do Doctors Consider Long-Term Effects in Psoriasis Care? Are Healthcare Professionals Considering Long-Term Effects When Managing Patients With Psoriasis? Edited by Vineeta Teotia https://www.medscape.com/viewarticle/are-healthcare-professionals-considering-long-term-effects-2025a1000xoq?ecd=mkm_ret_251218_mscpmrk_derm_skin-disorders_etid7963642&uac=148436CN&impID=7963642 ROSACEA Rosacea Underdiagnosed in This Cohort Rosacea Underdiagnosed in the Older Population: Look Beyond ‘Normal Skin Aging’ John Jesitus https://www.medscape.com/viewarticle/rosacea-underdiagnosed-older-population-look-beyond-normal-2025a1000w7e?ecd=mkm_ret_251218_mscpmrk_derm_skin-disorders_etid7963642&uac=148436CN&impID=7963642 November 19, 2025 Beyond Skin: How to Diagnose Ocular Rosacea Ocular Rosacea Underappreciated in Dermatology and Beyond John Jesitus https://www.medscape.com/viewarticle/ocular-rosacea-underappreciated-dermatology-and-beyond-2025a1000u9h?ecd=mkm_ret_251218_mscpmrk_derm_skin-disorders_etid7963642&uac=148436CN&impID=7963642 November 04, 2025 Does Vagus Nerve Therapy Improve Rosacea? Vagus Nerve Therapy Improved Rosacea Symptoms, Study Finds Edited by Deepa Varma https://www.medscape.com/viewarticle/vagus-nerve-therapy-improved-rosacea-symptoms-study-finds-2025a1000r2y?ecd=mkm_ret_251218_mscpmrk_derm_skin-disorders_etid7963642&uac=148436CN&impID=7963642 October 08, 2025 ATOPIC DERMATITIS Biologic Super Response Predicts Sustained Benefit Super Response to Biologics for Skin Diseases Often Predicts Sustained Benefit Ted Bosworth https://www.medscape.com/viewarticle/super-response-biologics-skin-diseases-often-predicts-2025a1000qkk?ecd=mkm_ret_251218_mscpmrk_derm_skin-disorders_etid7963642&uac=148436CN&impID=7963642 October 03, 2025 Higher Surgical Risks for Atopic Patients Atopic Conditions Linked to More Surgical Complications After Breast Reconstruction and Bone Grafting, Studies Find Lara Salahi https://www.medscape.com/viewarticle/atopic-conditions-linked-more-surgical-complications-after-2025a1000v2k?ecd=mkm_ret_251218_mscpmrk_derm_skin-disorders_etid7963642&uac=148436CN&impID=7963642 November 10, 2025 Broad Anti-Eczema Effects Seen With IL-22 Inhibitor Interleukin-22 Inhibitor Provides Broad Activity Against AD Biomarkers Ted Bosworth https://www.medscape.com/viewarticle/interleukin-22-inhibitor-provides-broad-activity-against-ad-2025a1000yw9?ecd=mkm_ret_251218_mscpmrk_derm_skin-disorders_etid7963642&uac=148436CN&impID=7963642 December 12, 2025

Phase 3 Data of Vonvendi for the Treatment of Von Willebrand Disease By: Madaline Spencer| Published on: Dec 19, 2025

https://checkrare.com/phase-3-data-of-vonvendi-for-the-treatment-of-von-willebrand-disease/ Latest Summaries https://checkrare.com/

RARE DISEASE LEARNING CENTERS +++++

CME PROGRAMS Immune Thrombotic Thrombocytopenic Purpura (iTTP) Clinical Research Highlights: ISTH 2025 https://checkrare.com/learning/p-isth2025-module3-immune-thrombotic-thrombocytopenic-purpura-ittp-clinical-research-highlights/ Shruti Chaturvedi, MD, provides a summary of clinically relevant data presented at the International Society of Thrombosis and Haemostatis Congress (ISTH 2025) that can enhance the care of patients with iTTP. CREDITS: 0.5 CME | DURATION: 30 minutes EXPIRES: 9/15/2026 | FEE: $0 Immune Thrombocytopenia Clinical Research Highlights: ISTH 2025 https://checkrare.com/learning/p-isth2025-module2-immune-thrombocytopenia-clinical-research-highlights/ Shruti Chaturvedi, MD, provides a summary of clinically relevant data presented at the International Society of Thrombosis and Haemostatis Congress (ISTH 2025) that can enhance the care of patients with ITP. CREDITS: 0.5 CME | DURATION: 30 minutes EXPIRES: 9/15/2026 | FEE: $0 Hemophilia Clinical Research Highlights: ISTH 2025 https://checkrare.com/learning/p-isth2025-module1-hemophilia-clinical-research-highlights/ Steven Pipe, MD, provides a summary of clinically relevant data presented at the International Society of Thrombosis and Haemostatis Congress (ISTH 2025) that can enhance the care of patients with hemophilia. CREDITS: 0.75 CME | DURATION: 45 minutes EXPIRES: 9/15/2026 | FEE: $0 RARE DISEASE LEARNING CENTERS Cutaneous T-Cell Lymphoma (CTCL) https://checkrare.com/cutaneous-t-cell-lymphoma-2/ Cutaneous T-cell lymphoma (CTCL) belongs to the non-Hodgkin lymphoma class of hematologic T-cell lymphoproliferative disorders. WHIM Syndrome https://checkrare.com/whim-syndrome/ WHIM syndrome is a rare, congenital primary immunodeficiency disorder associated with neutropenia that typically presents in childhood or adolescence.

FDA NEWS & CLINICAL PERSPECTIVES ++++ +++++

FDA NEWS 2025 Orphan Drugs: PDUFA Dates and FDA Approvals https://checkrare.com/2025-orphan-drugs-pdufa-dates-and-fda-approvals/ Rare diseases and orphan drugs are at the forefront of novel development and groundbreaking research. Almost half of all novel medications approved by the U.S. Food and Drug Administration (FDA) are orphan drugs. Below is the list of important regulatory dates for all orphan drugs for 2025. FDA Approves Ziftomenib for Relapsed/Refractory NPM1-Mutated Acute Myeloid Leukemia https://checkrare.com/fda-approves-ziftomenib-for-relapsed-refractory-npm1-mutated-acute-myeloid-leukemia/ The U.S. FDA has approved Komzifti (ziftomenib) for the treatment of relapsed or refractory (R/R) acute myeloid leukemia (AML) with susceptible NPM1 mutation. Darzalex Faspro for Patients With High-Risk Smoldering Multiple Myeloma https://checkrare.com/fda-approves-darzalex-faspro-for-patients-with-high-risk-smoldering-multiple-myeloma/ The U.S. FDA has approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) for the treatment of adult patients with high-risk smoldering multiple myeloma (HR-SMM). FDA Approves Revumenib for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia https://checkrare.com/fda-approves-revumenib-for-the-treatment-of-relapsed-refractory-acute-myeloid-leukemia/ The U.S. FDA has approved Revuforj (revumenib) for the treatment of relapsed/refractory acute myeloid leukemia (AML). CLINICAL PERSPECTIVES Long-Term Data From the AQUARIUS Study of Avacopan in Patients With GPA and MPA https://checkrare.com/long-term-data-from-the-aquarius-study-of-avacopan-in-patients-with-gpa-and-mpa/ Naomi Patel, MD, MPH, Rheumatologist at Massachusetts General Hospital, discusses long-term data from the AQUARIUS study of avacopan in patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Hemolytic Disease of the Fetus and Newborn: Outcomes of Intrauterine Transfusion and Patient Experiences https://checkrare.com/hemolytic-disease-of-the-fetus-and-newborn-outcomes-of-intrauterine-transfusion-and-patient-experiences/ May Lee Tjoa, PhD, Senior Global Medical Affairs Leader: Nipocalimab and Maternal-Fetal Immunology at Johnson & Johnson, discusses data on hemolytic disease of the fetus and newborn (HDFN) from the 2025 ISUOG World Congress on Ultrasound in Obstetrics and Gynecology. Rilzabrutinib Approval for Adult Patients With Immune Thrombocytopenia https://checkrare.com/rilzabrutinib-approval-for-adult-patients-with-immune-thrombocytopenia/ Amit Mehta, MD, Medical Oncologist, discusses data that led to the approval of Wayrilz (rilzabrutinib) for adult patients with immune thrombocytopenia (ITP). ISUOG World Congress 2025: Hemolytic Disease of the Fetus and Newborn https://checkrare.com/isuog-world-congress-2025-hemolytic-disease-of-the-fetus-and-newborn/ Jannine Williams, Compound Development Team Leader at Johnson & Johnson, discusses key takeaways from studies on hemolytic disease of the fetus and newborn (HDFN) presented at ISUOG World Congress 2025. Plans for Phase 2/3 Clinical Trial of Bexmarilimab Plus Standard of Care in Patients With Myelodysplastic Syndromes https://checkrare.com/plans-for-phase-2-3-clinical-trial-of-bexmarilimab-plus-standard-of-care-in-patients-with-myelodysplastic-syndromes/ Amer Zeidan, MBBS, MHS, Professor of Internal Medicine at Yale School of Medicine and Chief of the Division of Hematologic Malignancies at Yale Cancer Center, discusses plans for a phase 2/3 clinical trial testing bexmarilimab plus standard of care in patients with myelodysplastic syndromes (MDS).

Rare Disease Focus: Hematologic Disorders +++++

FEATURED ARTICLES Survey Finds Wide-Ranging Impact of X-Linked Hypophosphatemia (XLH) on Patient Experiences https://checkrare.com/survey-finds-wide-ranging-impact-of-x-linked-hypophosphatemia-on-patient-experiences/ Al Freedman, PhD, Rare Disease Psychologist and Rare Dad, and Jill H. Simmons, MD, Endocrinologist at Vanderbilt University Medical Center in Nashville, Tennessee highlight the burden of XLH on personal finances and out-of-pocket costs, overall health—physical, mental, and social—and access to expert care. New Staging Tool Available for Healthcare Providers Treating Patients With CTCL https://checkrare.com/new-staging-tool-available-for-healthcare-providers-treating-patients-with-ctcl/ Pamela Blair Allen, MD, MSc, Hematologist, discusses the new CTCL Staging Tool on PROBEinCTCL.com. Chronic Myeloid Leukemia: Overview, Treatment Options, and Advice for Newly Diagnosed Patients https://checkrare.com/chronic-myeloid-leukemia-overview-treatment-options-and-advice/ Jorge Cortes, MD, Director of the Georgia Cancer Center, provides an overview of chronic myeloid leukemia (CML), discusses treatment options, and offers advice to newly diagnosed patients. Cutaneous T-Cell Lymphoma: Natural History and the Need for Better Diagnostic and Treatment Efficacy https://checkrare.com/cutaneous-t-cell-lymphoma-natural-history-and-the-need-for-better-diagnostic-and-treatment-efficacy/ Henry Wong, MD, PhD, Dermatologist at the San Diego Veterans Hospital and the University of California San Diego (UCSD), discusses cutaneous T-cell lymphoma (CTCL). Chronic Myeloid Leukemia: Diagnosis and Treatment https://checkrare.com/chronic-myeloid-leukemia-diagnosis-and-treatment/ Michael Mauro, MD, Director of the Chronic Myeloid Leukemia Program at Memorial Sloan Kettering Cancer Center, discusses the diagnosis and treatment of chronic myeloid leukemia (CML).

Enhancing Impactful Patient-Centered Care for NMSC Through Meaningful Connections Authors: Dirk Schadendorf, MD; Emily Ruiz, MD, MPH

https://www.medscape.org/viewarticle/1002953?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251218-OUS-HONC-1002953-cta